1

1 COVID-19 outcomes in hospitalized puerperal, pregnant, and

2 neither pregnant nor puerperal women: a population study

- 3
- 4 Fabiano Elisei Serra¹, Rossana Pulcineli Vieira Francisco^{1*}, Patricia de Rossi^{2,3}, Maria de Lourdes
- 5 Brizot¹, Agatha Sacramento Rodrigues^{1,4*}

6

- 7 ¹Disciplina de Obstetrícia, Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina da
- 8 Universidade de São Paulo, São Paulo, São Paulo, Brazil
- 9 ² Curso de Medicina, Universidade de Santo Amaro (UNISA), São Paulo, São Paulo, Brazil
- 10 ³Gerência de Medicina Perinatal e Ginecologia, Conjunto Hospitalar do Mandaqui, São Paulo, São
- 11 Paulo, Brazil
- ⁴ Departamento de Estatística, Universidade Federal do Espírito Santo, Vitória, Espírito Santo, Brazil
- 13
- ^{*}Corresponding author
- 15 E-mail: agatha.rodrigues@ufes.br (ASR)

16

17 Abstract

- 18 **Objective** To compare hospitalized reproductive age women with COVID-19 who were pregnant,
- 19 puerperal, or neither one nor the other in terms of demographic and clinical characteristics and
- 20 disease progression using Brazilian epidemiological data.

2

21 Methods A retrospective analysis of the records of the Information System of the Epidemiological 22 Surveillance of Influenza of the Health Ministry of Brazil was performed. It included the data of 23 female patients aged 10 to 49 years hospitalized because of severe COVID-19 disease (RT-PCR+ for SARS-CoV-2), from February17, 2020 to January 02, 2021. They were separated into 3 groups: 24 25 pregnant, puerperal, and neither pregnant nor puerperal. General comparisons and then 26 adjustments for confounding variables (propensity score matching [PSM]) were made, using 27 demographic and clinical characteristics, disease progression (admission to the intensive care unit [ICU] and invasive or noninvasive ventilatory support), and outcome (cure or death). Deaths were 28 29 analyzed in each group according to comorbidities, invasive or noninvasive ventilatory support, and 30 admission to the ICU. 31 **Results** As many as 40,640 reproductive age women hospitalized for COVID-19 were identified: 32 3,372 were pregnant, 794 were puerperal, and 36,474 were neither pregnant nor puerperal. 33 Groups were significantly different in terms of demographic data and comorbidities. Pregnant and puerperal women were less likely to be symptomatic than the women who were neither one nor 34

the other. Pregnant women, however, had a higher frequency of cough, anosmia, and ageusia.
Puerperal women had a worse prognosis than pregnant women with respect to admission to the
ICU, invasive ventilatory support, and death.

38 Conclusion Puerperal women were at a higher risk for serious outcomes (need for the ICU, need for
39 invasive and noninvasive ventilatory support, and death) than pregnant women.

40

41 Introduction

42 COVID-19 is an infectious disease caused by the new coronavirus (SARS-CoV-2), and it has a clinical 43 spectrum ranging from absence of symptoms to severe illness and death. Widespread contagion

3

and the ability of the virus to disseminate led the World Health Organization (WHO) to declare a
pandemic state in March 2020 [1]. The high incidence has had a tremendous socioeconomic impact
worldwide. One day prior to the submission of this article (June 28, 2021), globally, there were
more than 180 million confirmed cases of COVID-19 and 3,923,238 deaths [2].

48 Since the beginning of the pandemic, the infection has been studied in the obstetric population to 49 understand its consequences and to prevent adverse maternal-fetal outcomes. The initial 50 publications describing COVID-19 cases in pregnant women in China, Europe, and North America 51 did not report increased severity and deaths compared to the general population [3-9]. Subsequent 52 studies, however, showed a higher likelihood of the need for admission to intensive care units 53 (ICUs) and mechanical ventilation [10-14]. The first maternal deaths were reported in the United Kingdom, Iran, United States, Mexico, and France [15-19].In Brazil, the high number of maternal 54 55 deaths due to COVID-19 has been attributed to factors such as high birth rate, poor nutrition and 56 health, difficult access to health services, and insufficient obstetric assistance [20,21].

57 Socioeconomic heterogeneity in Brazil is reflected in the quality of health services and in the 58 availability of hospital and ICU beds, having a great impact on health indicators of both pregnant 59 and puerperal women [22,23]. Understanding the disease and evaluating why the prognoses of 60 pregnant and puerperal women have been worse in this pandemic is relevant. We did not find any 61 studies comparing demographic and clinical characteristics and disease progression among 62 pregnant women, puerperal women, and neither pregnant nor puerperal women hospitalized with 63 COVID-19. Therefore, the authors of the present study aim to compare pregnant women, puerperal 64 women, and neither pregnant nor puerperal women according to data related to the SARS-CoV-2 65 infection by using population statistics from SIVEP-Gripe (System of Information about 66 Epidemiological Surveillance of Influenza) of the Health Ministry of Brazil.

4

68 Materials and methods

69 A retrospective analysis of the statistics from SIVEP-Gripe, a Brazilian national database containing 70 surveillance data on severe acute respiratory syndrome (SARS) was performed [24]. The notification 71 of SARS is compulsory in cases of the flu syndrome (acute respiratory condition, characterized by at 72 least two of the following signs and symptoms: fever [even if reported], chills, sore throat, 73 headache, cough, coryza, and disorders of taste or smell), accompanied by dyspnea/respiratory 74 distress, persistent chest pressure, oxygen saturation (SpO_2) below 95% in room air, or cyanosis. The 75 SIVEP-Gripe is notified of all cases of hospitalization both in public and in private hospitals, as well 76 as of all deaths caused by SARS-CoV-2, irrespective of hospitalization.

SIVEP-Gripe records include the following: demographic data (sex, age, skin color/ethnicity, obstetric status, schooling, city of residence); clinical data (signs and symptoms, risk factors/comorbidities); epidemiological data (previous flu vaccination, community-acquired infection, or nosocomial infection); laboratory and etiological diagnoses. There is also information about hospital admission, ICU admission, use of ventilatory support (invasive and noninvasive), and disease outcome (cure or death).

83 Data search covered epidemiological weeks 1 to 53 (December 29, 2019 - January 02, 2021), with 84 the last update on January 11, 2021; however, the first Brazilian records began in epidemiological 85 week 8 (first day of symptoms of the first confirmed case was on February 17, 2020). Search 86 included all data on female patients aged 10 to 49 years hospitalized with COVID-19, confirmed 87 with a positive RT-PCR result for SARS-CoV-2.Cases were excluded if they were unhospitalized or 88 unconfirmed with an RT-PCR for SARS-CoV-2, or if gender or pregnancy status were not recorded. 89 The result was 40,640 women hospitalized with COVID-19 (RT-PCR+) and aged between 10 and 49 90 years, who were divided into two groups: pregnant women (n=3,372) and nonpregnant women

5

91 (n=37,268). The latter were separated into puerperal (n=794) and neither pregnant nor puerperal
92 (n=36,474) (Figure 1).

Variables used in the analysis were age, pregnancy status, comorbidities, schooling, skin color/ethnicity, signs and symptoms, SARI (Severe Acute Respiratory Infection, defined as temperature \geq 38°C, cough, and onset in 10 days), SARI without fever, admission to ICU, respiratory support, and outcome (cure or death). Comorbidities reported were chronic cardiovascular, renal, neurological, hematologic, hepatic, and respiratory diseases, asthma, obesity, diabetes, and immunosuppression. Fever, cough, sore throat, dyspnea, respiratory discomfort, SpO₂<95%, diarrhea, vomiting, abdominal pain, fatigue, anosmia, and ageusia were the signs and symptoms.

Deaths were analyzed individually according to comorbidities, invasive and noninvasive respiratory
 support, and admission to ICU.

102 SIVEP-Gripe records are publicly available anonymized data. Therefore, according to Brazilian Ethics

regulatory requirements, there is no need for ethical approval by an Institutional Review Board.

104

105 **Data analysis**

106 Quantitative variables were summarized as mean and standard deviation. Qualitative variables 107 were displayed as absolute frequencies (n) and category percentages (%).

108 Nonparametric Kruskal-Wallis test was applied to compare the three study groups in terms of 109 quantitative variables. Chi-square test was used to evaluate the association between groups and 110 qualitative variables. Odds Ratio (OR) was considered as a measure of association to compare the 111 relative odds of the occurrence of the outcome of interest with a 95% confidence interval (95%CI). 112 Propensity score matching (PSM) was used to create weights for the observations to make the

three study groups equivalent in relation to the confounding variables [25]. The first analysis, used

114	to compare the symptoms between groups, included age, ethnicity, chronic cardiovascular disease,
115	asthma, diabetes, immunosuppression, and obesity. The second one, comparing the outcomes,
116	included the same variables plus schooling, Federative Unit of Brazil, and respiratory symptoms.
117	The analyses were performed with the statistical R software (R Foundation for Statistical Computing
118	Platform, version 4.0.3) [26] and PSM was carried out with the R Weightlt package [27].

119

120 **Results**

A total of 40,640 reproductive age women hospitalized with a positive RT-PCR for SARS-CoV-2 result were identified. Of these, 3,372 were pregnant and 37,268 were not pregnant (Figure 1). Nonpregnant women comprised 794 puerperal women and 36,474 women who were neither pregnant nor puerperal. Groups differed significantly related to demographic data and comorbidities (Table 1). The group of neither pregnant nor puerperal women had the highest rate of comorbidities.

127

128 Figure 1: Study profile

- 130Table 1. Demographic and clinical characteristics of reproductive age women with COVID-19
- according to gestational status Brazil, February 17, 2020 January 02, 2021

Characteristics	Neither pregnant nor puerperal	Pregnant	Puerperal	р
Age (years)				
Mean ± SD	38.22 ± 8.25	29.64 ± 6.93	30.24 ± 7.34	<0.0001
Age bracket (years)	n (%)	n (%)	n (%)	
<20	1,009 (2.8)	250 (7.4)	61 (7.7)	<0.0001
20-34	9,629 (26.4)	2,244 (66.5)	494 (62.2)	
>34	2,5836 (70.8)	878 (26.0)	239 (30.1)	
Total	36,474	3,372	794	
Skin color/Ethnicity	n (%)	n (%)	n (%)	
White	15,418 (54.0)	1,102 (40.5)	238 (37.2)	<0.0001
Black	1,679 (5.9)	192 (7.1)	46 (7.2)	

7

Yellow	359 (1.3)	22 (1 2)	4 (0.6)	
Brown	10,976 (38.5)	33 (1.2) 1,382 (50.8)	4 (0.6) 348 (54.4)	
Indigenous	,		· /	
Total	97 (0.3)	13 (0.5)	4 (0.6)	
	28,529 (100)	2,722 (100)	640 (100)	
Schooling	n (%)	n (%)	n (%)	
No schooling	219 (1.4)	7 (0.5)	2 (0.6)	
Up to high school	3,661 (23.7)	360 (25.1)	81 (24.5)	<0.0001
High school	7,532 (48.7)	790 (55.1)	179 (54.2)	
College	4,058 (26.2)	277 (19.3)	68 (20.6)	
Total	15,470 (100)	1,434 (100)	330 (100)	
Risk factors and comorbidities	n (%)	n (%)	n (%)	
Chronic cardiovascular disease (n=14,976)	5780/13,330 (43.4)	214/1,141 (18.8)	77/505 (15.2)	<0.0001
Chronic hematologic disease (n=12,901)	356/11,340 (3.1)	16/1,081 (1.5)	11/480 (2.3)	0.006
Chronic hepatic disease (n=12,769)	189/11,226 (1.7)	8/1,066 (0.8)	4/477 (0.8)	0.0273
Asthma (n=13,426)	1883/11,821 (15.9)	139/1,119 (12.4)	33/486 (6.8)	<0.0001
Diabetes (n=14,575)	4825/12,934 (37.3)	241/1,151 (20.9)	61/490 (12.4)	<0.0001
Chronic neurological disease (n=12,933)	568/11,377 (5.0)	25/1,078 (2.3)	5/478 (1.0)	<0.0001
Chronic lung disease (n=12,945)	579/11,390 (5.1)	23/1,075 (2.1)	5/480 (1.0)	<0.0001
Immunodepression (n=13,137)	1,289/11,578 (11.1)	40/1,078 (3.7)	18/481 (3.7)	<0.0001
Chronic renal disease (n=13,047)	1,080/11,495 (9.4)	24/1,073 (2.2)	12/479 (2.5)	<0.0001
Obesity (n=13,713)	3,741/12,135 (30.8)	143/1,097 (13.0)	53/481 (11.0)	<0.0001
Metabolic syndrome (n=12,509)	422/10,998 (3.8)	7/1,044 (0.7)	7/467 (1.5)	<0.0001
Number of comorbidities (n=11,958)	n (%)	n (%)	n (%)	< 0.0001
0	2,022/10,502 (19.3)	576/999 (57.7)	335/457 (73.3)	
1-2	7,681/10,502 (73.1)	408/999 (40.8)	106/457 (23.2)	
>2	799/10,502 (7.6)	15/999 (1.5)	16/457 (3.5)	

132

133

Table 2 shows the results of the comparison of COVID-19 symptoms before and after PSM in the three study groups. Both pregnant and puerperal women had a smaller chance of fever, cough, sore throat, dyspnea, respiratory discomfort, SpO₂<95%, diarrhea, vomiting, fatigue, SARI, and SARI without fever than neither pregnant nor puerperal women. Pregnant women had anosmia and ageusia more frequently than the others. Puerperal women had fewer chance of fever, coughing, vomiting, SARI, and SARI without fever than pregnant women; however, their oxygen saturation level was more frequently lower than 95% at hospital admission.

8

141

142

143 Table 2. COVID-19 signs, symptoms, and infection in pregnant, puerperal, and neither pregnant

144 nor puerperal reproductive age women before and after propensity score matching –

145 Brazil, February 17, 2020 – January 02, 2021

	Neither pregnant nor puerperal	Pregnant	Puerperal	G	roup comparise	on	(age + ethnio	comparison aft city + cardiopat s + immunosup obesity)	thy + asthma
Signs, symptoms, and infection	n (%)	n (%)	n (%)	Pregnant vs. NPrNPu OR (95% Cl)	Puerperal vs. NPrNPu OR (95% Cl)	Puerperal vs. Pregnant OR (95% Cl)	Pregnant vs. NPrNPu OR (95% Cl)	Puerperal vs. NPrNPu OR (95% Cl)	Puerperal vs. Pregnant OR (95% Cl)
Fe ver (n=36,371)	24,297/32,70	2,038/2,98 3 (68.3)	424/686 (61.8)	0.75 (0.69 -0.81)	0.56 (0.48 -0.65)	0.75 (0.63 -0.89)	0.78 (0.69 -0.88)	0.63 (0.53 - 0.74)	0.81 (0.67 - 0.93)
Cough (n=37,101)	2 (74.3) 27,305/33,32 4 (81.9)	2,408/3,08 5 (78.1)	475/692 (68.6)	0.78 (0.72	-0.83) 0.48 (0.41 -0,57)	0.62 (0.51	1.19 (1.04 - 1.36)	0.81 (0.67 - 0.97)	- 0.93) 0.68 (0.56 - 0.82)
Sore throat (n=31,474)	8,854/28,242 (31.4)	724/2,629 (27.5)	156/603 (25.9)	0.83 (0.76 -0,91)	0.76 (0.63 -0.92)	0.92 (0.75 1.12)	0 88 (0 78 - 1 0 1)	0.90 (0.74 - 1.10)	1.02 (0.83 - 1.26)
Dyspnea (n=36,272)	25,134/32,66 4 (76.9)	1,761/2,94 0 (59.9)	381/668 (57.0)	0.45 (0.41 -0.48)	0.40 (0.34 -0.47)	0.89 (0.75 1.05)	0.54 (0.48 -0.61)	0.54 (0.45 - 0.64)	1.00 (0.84 - 1.20)
Respiratory discomfort (n=34,023)	20, 158/30, 60 0 (65. 9)	1,374/2,77 1 (49.6)	341/652 (52.3)	0.51 (0.47 -0.55)	0.57 (0.49 0.66)	1.11 (0.94 1.32)	0.60 (0.54 0.68)	0.73 (0.62 0.87)	1.21(1.02 - 1.45)
SpO ₂ <95% (n=33,482)	17, 109/30, 13 7 (56.8)	860/2,708 (31.8)	291/637 (45.7)	0.35 (0.32	0.64 (0.55 -0.75)	1.81 (1.52 - 2.15)	0.40 (0.35	0.79 (0.67 - 0.94)	1.99 (1.65 - 2.39)
At least 1 respiratory symptom (n=37,726)	30,208/34,00 2 (88.8)	2,177/3,02 1 (72.1)	490/703 (69.7)	0.32 (0.30 -0.35)	0.29 (0.25 0.34)	0.89 (0.75 1.07)	0.44 (0.38 - 0.51)	0.43 (0.36 - 0.53)	0.98 (0.81 - 1.18)
(n=37,728) Diarrhea (n=30,907)	6,387/27,758 (23.0)	335/2,574 (13.0)	65/575 (11.3)	0.50 (0.44 - 0.56)	0.43 (0.33 -0.55)	0.85 (0.64 - 1.13)	0.61 (0.52 -0.71)	0.53 (0.41 - 0.70)	0.88 (0.66 - 1.18)
Vomiting (n=30,342)	4,148/27,206 (15.2)	342/2,566 (13.3)	45/570 (7.9)	0.86 (0.76	0.48 (0.35	0.56 (0.40	0.75 (0.63	0.47 (0.34	0.63 (0.45
Abdominal pain (n=15,775) Fatigue	13.47/14,360 (9.4) 4,383/14,780	117/1,175 (10.0) 263/1,191	20/240 (8.3) 47/245	1.07 (0.87 - 1.30) 0.67 (0.58	0.88 (0.54 - 1.37) 0.56 (0.41	0.83 (0.49 - 1.33) 0.84 (0.59	0.94 (0.69 - 1.28) 0.95 (0.78	0.75 (0.45 - 1.24) 0.86 (0.61	0.80 (0.48- 1.33) 0.90 (0.63
(n=16,216) Anosmia	(29.7) 3,216/14,718	(22.1)	(19.2) 51/260	-0.77) 1.35 (1.18	-0.77) 0.87 (0.64	- 1.18) 0.65 (0.46	- 1.15) 1.79 (1.48	- 1.20) 1.26 (0.91	- 1.29) 0.70 (0.50
(n=16,202)	(219)	(27.4)	(19.6)	- 1.54)	- 1.18)	- 0.90)	- 2.17)	- 1.75)	- 0.99)
Ageusia (n=16,103)	3,121/14,634 (21.3)	297/1,212 (24.5)	45/257 (17.5)	1.20 (1.04 - 1.37)	0.79 (0.56 1.08)	0.66 (0.46 0.92)	1.70 (1.41 2.04)	1.17 (0.84 - 1.64)	0.69 (0.48 0.99)
SARI (n=34,118)	18,089/30,68 9 (58.9)	1,308/2,79 5 (46.8)	242/634 (38.2)	0.61 (0.57 -0.66)	0.43 (0.37 -0.51)	0.70 (0.59 0.84)	0.78 (0.70 -0.88)	0.58 (0.49 0.69)	0.74 (0.62 - 0.89)
SARI without fever (n=35,939)	24,504/32,35 3 (75.7)	1,816/2,92 5 (62.1)	351/661 (53.1)	0.52 (0.48 -0.57)	0.36 (0.31 -0.42)	0.69 (0.58 0.82)	0.75 (0.67 0.85)	0.57 (0.48 0.67)	0.75 (0.63 0.90)
Hospital-acquired infection (n=30,722)	760/27,508 (2.8)	37/2,617 (1.4)	34/597 (5.7)	0.51 (0.36- 0.70)	2.13 (1.47 2.99)	4.21 (2.61 6.78)	0.38 (0.24 - 0.59)	1.28 (0.85 - 1.93)	3.38 (2.01 - 5.69)

146 PSM, Propensity Score Matching; NPrNPu, neither pregnant nor puerperal; OR, Odds Ratio; 95%Cl, 95% confidence

147 interval; SpO2, oxygen saturation in room air; SARI, temperature \geq 38°C, cough, and onset in 10 days

148

A remarkable fact related to hospital-acquired COVID-19 is that pregnant women developed the disease less frequently (1.4%) than neither pregnant nor puerperal women (2.8%) and puerperal women (5.7%).

A PSM analysis of the statistical differences between the groups, especially regarding age, skin color/ethnicity, and comorbidities, showed that pregnant women had cough more frequently than neither pregnant nor puerperal women. Sore throat and fatigue did not differ significantly between the groups. The remainder of the PSM analysis comparing pregnant and puerperal women with neither pregnant nor puerperal yielded similar results to the general analysis. When comparing puerperal to pregnant women, the only difference was a higher frequency of respiratory discomfort in the first group.

Pregnant, compared to neither pregnant nor puerperal women, were less likely to have any of the study outcomes (admission to ICU, invasive and noninvasive respiratory support, and death). On the other hand, puerperal women, when contrasted with neither pregnant nor puerperal, were more likely to be admitted to the ICU and less likely to need noninvasive support. Puerperal had a higher risk of needing admission to the ICU, requiring invasive respiratory support, and dying, than pregnant women (Table 3).

166

167Table 3. Comparison of outcomes in pregnant, puerperal, and neither pregnant nor puerperal168reproductive age women before and after propensity score matching– Brazil, February 17, 2020 –

Outcome	Neither pregnant nor puerperal	Pregnant	Puerpera I	Gro	Group comparison			Group comparison after PSM (age + ethnicity + schooling + FUB + chronic cardiovascular disease + asthma + diabetes + immunosuppression + obesity + respiratory symptoms)		
	n (%)	n (%)	n (%)	Pregnant vs. NPrNPu OR (95% Cl)	Puerperal vs. NPrNPu OR (95% Cl)	Puerpera l vs. Pregnant OR (95%	Pregnant vs. NPrNPu OR (95%	Puerpera l vs. NPrNPu OR (95%	Puerpera l vs. Pregnant OR (95%	

10

							CI)	CI)	CI)	CI)
ICI adı	mission	8014/29,36	574/2,72	244/680	0.71 (0.65 –	1.49 (1.27 –	2.09	0.58	1.14	1.97
	2,769)	8 (27.3)	1 (21.1)	(35.9)	0.78)	1.75)	(1.74 –	(0.48 –	(0. 91 –	(1.62 –
(11-52	., 703	0(27.3)	1 (21.1)	(33.9)	0.78	1.75)	2.51)	0.71)	1.43)	2.40)
Mandilada	No	n=28, 199	n=2, 598	n=660						
Ventilato	v	2 5 2 6		422		1.23 (1.00 – 1.51)	2.96	0.48	1.29	2.71
ry .	Yes,	3,536	209 (8.0)	133	0.42 (0.36-		(2.31-	(0.33 -	(0.96 -	(1.91 -
support	invasive	(12.5)		(20.2)	0.48)		3.79)	0.68)	1.74)	3.82)
(n=31,45	Yes,	40.040	760	170	0.44/0.07		1.09	0.59	0.65	1.10
7)	no ninvas	nvas	178		0.44 (0.37 –	(0.89 –	(0.47 -	(0.51 -	(0.86 -	
	ive	(46.9)	(29.4)	(27.0)	0.44)	0.53)	1.33)	0.75)	0.83)	1.42)
	4.524/22.0 401/	191/2 00	101/2 00 111/715	0.40/0.24	1.15 (0.94 -	2.85	0.43	1.09	2.51	
Death (n=35,700)		4,534/32,0	181/2,90	114/715	0.40 (0.34 -	•	(2.22 —	(0.34 –	(0. 86 —	(1.90 -
		81 (14. 1)	4 (6.2)	(15.9)	0.47)	1.41)	3.66)	0.54)	1.38)	3.31)

PSM, Propensity Score Matching; NPrNPu, neither pregnant nor puerperal; OR, Odds Ratio; 95%Cl, 95%
 confidence interval; FUB, Federative Unit of Brazil; ICU, Intensive Care Unit

After PSM (with the inclusion schooling, Federative Unit of Brazil, and respiratory symptoms variables), the only difference between this analysis and the general analysis was that puerperal women were no longer more likely than neither pregnant nor puerperal women to be admitted to ICU, while maintaining a worse prognosis than that of pregnant women with respect to admission to the ICU, invasive ventilatory support, and death.

Pregnant women with chronic cardiovascular or renal disease, 178 asthma, diabetes, 179 immunodepression, or obesity, and those in the ICU, or those who received ventilatory support 180 were less likely to die than neither pregnant nor puerperal women with the same characteristics (Table 4). Puerperal women did not differ significantly from neither pregnant nor puerperal 181 regarding the study variables. Puerperal women had a greater likelihood of dying than pregnant 182 183 women when both had asthma, diabetes, or obesity, or when received noninvasive ventilatory 184 support, or were admitted to the ICU. After PSM, of women with chronic cardiovascular disease or 185 diabetes and of those admitted to ICU or who received noninvasive support, pregnant were less 186 likely to die than neither pregnant nor puerperal women.

11

188 Table 4. Comparison of the death rates of pregnant, puerperal, and neither pregnant nor 189 puerperal reproductive age women before and after propensity score matching according to comorbidities, ICU admission, and ventilatory support – Brazil, February 17, 2020 – January 02, 190

2021 191

Variable		Death rate		Group comparison			Group comparison after PSM (age + ethnicity + schooling + FUB + chronic cardiovascular disease + asthma + diabetes + immunosuppression + obesity + respiratory symptoms)		
	Neither pregnant nor puerperal	Pregnant	Puerperal	Pregnant vs. NPrNPu OR (95% Cl)	Puerperal vs. NPrNPu OR (95% Cl)	Puerperal vs. Pregnant OR (95% Cl)	Pregnant vs. NPrNPu OR (95% Cl)	Puerperal vs. NPrNPu OR (95% Cl)	Puerperal vs. Pregnant OR (95% Cl)
Chronic cardiovascular disease (n=5, 349)	1,159/5,093 (22.8)	24/186 (12.9)	15/70 (21.4)	0.51 (0.32 — 0.77)	0.93 (0.51 -1.62)	1.84 (0.88 - 3.75)	0.47 (0.28 – 0.79)	0.96 (0.52 - 1.75)	2.02 (0.97 - 4.24)
Asthma (n=1,804)	254/1,658 (15.3)	8/119 (6.7)	6/27 (22.2)	0.41 (0.18 - 0.79)	1.61 (0.58 - 3.82)	3.93 (1.16 - 12.75)	0.56 (0.20 1.59)	2.68 (0.99 - 7.20)	4.79 (1.27 - 18.02)
Diabetes (n=4,539)	1,143/4,268 (26.8)	27/212 (12.7)	19/59 (32.2)	0.40 (0.26 – 0.59)	1.30 (0.73 - 2.23)	3.24 (1.62 - 6.41)	0.43 (0.26 - 0.72)	1.52 (0.85 - 2.70)	3 50 (1 70 - 7 22)
Immunode pression (n=1,213)	408/1,159 (35.2)	6/36 (16.7)	3/18 (16.7)	0.38 (0.14 – 0.85)	0.38 (0.08 - 1.18)	1.02 (0.18 -4.62)	0.54 (0.19 – 1.48)	0.55 (0.15 - 1.98)	1.03 (0.21 - 5.01)
Chronic Renal disease (n=995)	385/963 (40.0)	2/21 (9.5)	4/11 (36.4)	0.17 (0.02 – 0.59)	0.87 (0.22 - 2.98)	4.96 (0.74 -47.5)	0.59 (0.12 – 2.82)	1.52 (0.41 - 5.65)	2.56 (0.37 - 17.61)
Obesity (n= 3,500)	762/3,327 (22.9)	19/125 (15.2)	15/48 (31.2)	0.61 (0.36 – 0.97)	1.54 (0.80 - 2.80)	2.52 (1.14 -5.55)	0.80 (0.42 – 1.53)	2.29 (1.22 - 4.30)	2.84 (1.19 - 6.78)
Invasive respiratory support (n=3,878)	2,249/3,536 (63.6)	104/209 (49.8)	77/133 (57.9)	0.57 (0.43 – 0.75)	0.79 (0.55 - 1.12)	1.39 (0.89 -2.16)	0.68 (0.38 - 1.21)	0.83 (0.46 - 1.48)	1.22 (0.75 - 1.99)
Noninvasive respiratory support (n=14,154)	1246/13,213 (9.4)	37/763 (4.8)	18/178 (10.1)	0.49 (0.35 – 0.69)	1.09 (0.64 - 1.73)	2.21 (1.20 - 3.95)	0.48 (0.30 – 0.77)	0.92 (0.53 - 1.60)	1.93 (1.02 - 3.63)
ICU admission (n=8,832)	2,755/8,014 (34.4)	127/574 (22.1)	90/244 (36.9)	0.54 (0.44 – 0.66)	1.12 (0.85 - 1.45)	2.06 (1.48 - 2.85)	0.69 (0.48 — 0.99)	1.27 (0.88 - 1.83)	1.84 (1.28 - 2.64)

192

PSM, Propensity Score Matching; NPrNPu, neither pregnant nor puerperal; OR, Odds Ratio; 95%Cl, 95%

193 confidence interval; FUB, Federative Unit of Brazil; ICU, Intensive Care Unit

194

Discussion 195

196 The results of the current analysis show that at hospital admission, both pregnant and puerperal 197 women, in general, presented a lower rate of symptoms than neither pregnant nor puerperal 198 women, except for cough, anosmia, and ageusia of pregnant women. On the other hand, the

contrast between puerperal and pregnant women revealed that the former had a higher rate of respiratory discomfort and SpO₂<95%, as well as a higher likelihood of ICU admission, invasive ventilatory support, and death. Therefore, our study data suggest that puerperal women are at a higher risk of severe outcomes than pregnant women and run as much risk as neither pregnant nor puerperal women.

At the beginning of the COVID-19 pandemic, the initial publications addressing infections in pregnant women were case reports, short case series, and systematic reviews. Given the low case numbers, the first impression was that pregnant and puerperal women were not at a higher risk for complications and death than the non-obstetric population [3-9]. As epidemiological weeks passed, new studies reported a greater need for invasive ventilation and ICU and an increased number of deaths in the obstetric population [10,11,13,14,16,28].

210 The United States Centers for Disease Control and Prevention published data from January 22 to 211 October 3, 2020, comprising 1,300,938 women with COVID-19. Of these, 23,434 were symptomatic pregnant women. In that study, pregnant women, as opposed to nonpregnant, ran a higher risk of 212 213 ICU admission, invasive ventilation, extracorporeal membrane oxygenation (ECMO), and death 214 [13].In our study, the sample included only hospitalized women with SARS-CoV-2. After PSM, our 215 results differed from the CDC results as follows: pregnant women were less likely to be admitted to 216 an ICU (OR 0.58), to need invasive ventilation (OR 0.48), or to die (OR 0.43) than nonpregnant; 217 however, puerperal women were at a higher risk of death than pregnant women. Among all the 218 signs and symptoms reported in the CDC study, cough, headache, myalgia, and fever were the most 219 common and they were mostly reported by the nonpregnantwomen [13]. Our data also show that 220 the most common signs and symptoms in all groups were cough, dyspnea, and fever, with both 221 pregnant and puerperal women showing fewer symptoms than nonpregnant women. Nevertheless,

13

222 pregnant women had anosmia and dysgeusia significantly more frequently than the other two 223 groups.

224 In a study with the Brazilian population involving 2,475 pregnant and puerperal women with SARS, 72% of whom had COVID-19 confirmed by RT-PCR, 590 had unfavorable outcomes. The risk 225 226 increased 2.4 times when the SARS notification occurred in the postpartum period rather than 227 during pregnancy [21]. In the present study, all cases were confirmed by RT-PCR, and the 228 unfavorable outcomes (ICU, mechanical ventilation, and death) were analyzed separately for each 229 group of women (pregnant, puerperal, and neither pregnant nor puerperal) to identify the specific 230 risks for each outcome and each group. After pairing with PSM, puerperal women were more likely 231 than pregnant women to be admitted to ICU (OR 1.97), to receive invasive respiratory support (OR 232 2.71), to die (OR 2.51), and to acquire the COVID-19 infection in hospital (OR 3.38).

233 In Mexico, a study including a cohort of 5,183 pregnant women and 175,905 nonpregnant women 234 with COVID-19 compared the two groups regarding death, pneumonia, invasive respiratory 235 support, and ICU admission. The data (comorbidities, age, language, and health insurance level) 236 were analyzed with and without adjustment for propensity score matching. After pairing, pregnant 237 women showed a higher likelihood of death (OR 1.84), pneumonia (OR 1.86), and ICU admission 238 (OR 1.86) than nonpregnant, but both groups ran a similar risk of invasive respiratory support (OR 239 0.93) [14]. The study, however, did not evaluate either group separately. In contrast to the Mexican 240 study, our data, following adjustments, revealed that pregnant women had a lower likelihood of 241 death (OR 0.43), invasive respiratory support (OR 0.48), and ICU admission (OR 0.58) than both 242 neither pregnant nor puerperal women and puerperal women. It should be mentioned that the two 243 studies are not comparable, given that the Mexican study, on the one hand, included women who 244 were not hospitalized and, on the other hand, divided reproductive age women into only two 245 groups, pregnant and nonpregnant.

14

Our study has the following strong points: 1) the use of a national database with a large sample size number and no duplicates; 2) patients who were hospitalized due to severe acute respiratory syndrome, which was confirmed by the RT-PCR laboratory test; 3) discrimination between pregnant and puerperal women for a more accurate analysis of the obstetric population; 4) the use of paired comparison analysis through propensity score matching, which allowed adjustments for the demographic data and comorbidities to evaluate symptoms and outcomes.

As study limitations, a comparison with those infected with COVID-19 in the general population could not be made because only hospitalized cases with SARS and deaths are notified, and bias introduced by missing variables cannot be eliminated.

In the present study, the death risk of each comorbidity was identified separately for the three groups of women: pregnant, puerperal, and neither pregnant nor puerperal. This enabled the use of ORs included in the risk calculations for the COVID-19 progression at hospital admission.

Since puerperal women were at a higher risk for the most severe outcomes (need for ICU, use of invasive ventilatory support, and death), the fact that pregnancy is over must not underestimate the severity risks. Thus, in those cases in which the SARS-CoV-2 infection is acquired at the end of pregnancy, the delivery should be considered only after overcoming the disease. When it is acquired during the puerperal period, health professionals should remain alert to the severityrelated risks. It would be ideal if all women were vaccinated to minimize the risks of SARS-CoV-2 infection and if they adhered to protection measures to prevent contamination by the virus.

As puerperal turned out to be a higher risk group than pregnant women among those hospitalized due to COVID-19, we need more studies comparing these groups. Furthermore, it should be considered that childbirth might influence the progression of COVID-19.

268

269 Data availability statement

The data that support the findings of this study are available in GitHub repository at <u>https://github.com/observatorioobstetrico/paper_covid19_groups</u>. These data were derived from the following resources available in the public domain: <u>https://opendatasus.saude.gov.br/dataset/bd-srag-2020</u> obtained on January 11, 2021.

274

275 Acknowledgments

This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [INV-027961].

277 Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License

- has already been assigned to the Author Accepted Manuscript version that might arise from this
- 279 submission.
- 280

281 **References**

1. World Health Organization. WHO Director-General's opening remarks at the media briefing on

283 COVID-19 - 11 March 2020. Available from: https://www.who.int/director-

284 general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-

285 19---11-march-2020

286 2. WHO COVID-19 Dashboard [Internet]. Geneva: World Health Organization, 2021 - [cited 2021

287 Jun 28]. Available from: https://covid19.who.int/

Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W,et al. Clinical characteristics and intrauterine
 vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective
 review of medical records. *Lancet*. 2020;395(10226):809-815.

4. Mullins E, Evans D, Viner RM, O'Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid

review. Ultrasound Obstet Gynecol. 2020;55(5):586-592.

16

- 293 5. Kasraeian M, Zare M, Vafaei H, Asadi N, Faraji A, Bazrafshan K, et al. COVID-19 pneumonia and
- 294 pregnancy; a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2020;1-8.
- 295 6. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A systematic review
- of 108 pregnancies. Acta ObstetGynecolScand. 2020;99(7):823-829.
- 297 7. Di Toro F, Gjoka M, Di Lorenzo G, De Santo D, De Seta F, Maso G, et al. Impact of COVID-19 on
- 298 maternal and neonatal outcomes: a systematic review and meta-analysis. Clin Microbiol Infect.
- 299 2021;27(1):36-46.
- 300 8. Elshafeey F, Magdi R, Hindi N, Elshebiny M, Farrag N, Mahdy S, et al. A systematic scoping review
- of COVID-19 during pregnancy and childbirth. Int J Gynaecol Obstet. 2020;150(1):47-52.
- 9. Huntley BJF, Huntley ES, Di Mascio D, Chen T, Berghella V, Chauhan SP. Rates of Maternal and
 Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute
- Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review. Obstet Gynecol.
- 305 2020;136(2):303-312.

306 10. Sentilhes L, De Marcillac F, Jouffrieau C, Kuhn P, Thuet V, Hansmann Y, et al. Coronavirus
307 disease 2019 in pregnancy was associated with maternal morbidity and preterm birth. Am J Obstet
308 Gynecol. 2020;223(6):914.e1-914.e15.

309 11. Badr DA, Mattern J, Carlin A, Cordier AG, Maillart E, El Hachem L, et al. Are clinical outcomes
310 worse for pregnant women at ≥20 weeks' gestation infected with coronavirus disease 2019? A
311 multicenter case-control study with propensity score matching. Am J Obstet Gynecol.
312 2020;223(5):764-768.

12. Allotey J, Stallings E, Bonet M,Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk
factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living
systematic review and meta-analysis. BMJ. 2020;370:m3320.

316	13. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics
317	of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by
318	Pregnancy Status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep.
319	2020;69(44):1641-1647.
320	14. Martinez-Portilla RJ, Sotiriadis A, Chatzakis C, Torres-Torres J, Espino Y Sosa S, et al. Pregnant
321	women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score
322	matched analysis of a nationwide prospective cohort (COV19Mx). Ultrasound Obstet Gynecol.
323	2021;57(2):224-231.
324	15. Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, et al. Characteristics and outcomes
325	of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national
326	population-based cohort study. BMJ. 2020;369:m2107.
327	16. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, Seferovic MD, Aski SK, Arian SE, et al. Maternal
328	death due to COVID-19. Am J Obstet Gynecol. 2020;223(1):109.e1-109.e16.
329	17. Vallejo V, Ilagan JG. A Postpartum Death Due to Coronavirus Disease 2019 (COVID-19) in the
330	United States. ObstetGynecol. 2020;136(1):52-55.
331	18. Lumbreras-Marquez MI, Campos-Zamora M, Lizaola-Diaz de Leon H, Farber MK. Maternal
332	mortality from COVID-19 in Mexico. Int J Gynaecol Obstet. 2020;150(2):266-267.
333	19. Kayem G, Lecarpentier E, Deruelle P, Bretelle F, Azria E, Blanc J, et al. A snapshot of the Covid-19
334	pandemic among pregnant women in France. J GynecolObstet Hum Reprod. 2020;49(7):101826.
335	20. Takemoto MLS, Menezes MO, Andreucci CB, Nakamura-Pereira M, Amorim MMR, Katz L,et al.
336	The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting. Int J Gynaecol Obstet.
337	2020;151(1):154-156.

- 338 21. Menezes MO, Takemoto MLS, Nakamura-Pereira M, Katz L, Amorim MMR, Salgado HO, et al.
- 339 Risk factors for adverse outcomes among pregnant and postpartum women with acute respiratory
- distress syndrome due to COVID-19 in Brazil. Int J Gynaecol Obstet. 2020;151(3):415-423.
- 341 22. Amorim MMR, Soligo Takemoto ML, Fonseca EBD. Maternal deaths with coronavirus disease
- 2019: a different outcome from low- to middle-resource countries? Am J Obstet Gynecol.
 2020;223(2):298-299.
- 344 23. Takemoto M, Menezes MO, Andreucci CB, Knobel R, Sousa L, Katz L, et al. Clinical characteristics
- and risk factors for mortality in obstetric patients with severe COVID-19 in Brazil: a surveillance
- 346 database analysis. BJOG. 2020;127(13):1618-1626.
- 347 24. Brasil. Ministério da Saúde. Definição de Caso e Notificação. Available from:
 348 https://www.gov.br/saude/pt-br/coronavirus/artigos/definicao-e-casos-suspeitos. Retrieved
 349 04/04/2021.
- 25. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of
 Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424.
- 26. R Core Team. R: A language and environment for statistical computing. R Foundation for
- 353 Statistical Computing, Vienna, Austria, 2020. Version 4.0.3 [software]. 2020 Oct 10 [cited 2021 Jan
- 354 15]. Available from: https://www.r-project.org/
- 27. Greifer N. Weightlt: Weighting for Covariate Balance in Observational Studies. R package
 version 0.10.2 [software]. 2020 Sep 20 [cited 2021 Jan 15]. Available from: https://cran.rproject.org/package=Weightlt
- 358 28. Collin J, Byström E, Carnahan A, Ahrne M. Public Health Agency of Sweden's Brief Report:
- 359 Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection
- in intensive care in Sweden. Acta ObstetGynecol Scand. 2020;99(7):819-822.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

